GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gensight Biologics SA (XPAR:SIGHT) » Definitions » Equity-to-Asset

Gensight Biologics (XPAR:SIGHT) Equity-to-Asset : -3.36 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Gensight Biologics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Gensight Biologics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €-30.67 Mil. Gensight Biologics's Total Assets for the quarter that ended in Dec. 2023 was €9.13 Mil. Therefore, Gensight Biologics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was -3.36.

The historical rank and industry rank for Gensight Biologics's Equity-to-Asset or its related term are showing as below:

XPAR:SIGHT' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.36   Med: 0.49   Max: 0.9
Current: -3.36

During the past 12 years, the highest Equity to Asset Ratio of Gensight Biologics was 0.90. The lowest was -3.36. And the median was 0.49.

XPAR:SIGHT's Equity-to-Asset is ranked worse than
95.71% of 1562 companies
in the Biotechnology industry
Industry Median: 0.67 vs XPAR:SIGHT: -3.36

Gensight Biologics Equity-to-Asset Historical Data

The historical data trend for Gensight Biologics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gensight Biologics Equity-to-Asset Chart

Gensight Biologics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.32 0.25 0.28 -0.59 -3.36

Gensight Biologics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.08 -0.59 -1.62 -3.36

Competitive Comparison of Gensight Biologics's Equity-to-Asset

For the Biotechnology subindustry, Gensight Biologics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gensight Biologics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gensight Biologics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Gensight Biologics's Equity-to-Asset falls into.



Gensight Biologics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Gensight Biologics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-30.668/9.132
=-3.36

Gensight Biologics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-30.668/9.132
=-3.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gensight Biologics  (XPAR:SIGHT) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Gensight Biologics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Gensight Biologics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Gensight Biologics (XPAR:SIGHT) Business Description

Traded in Other Exchanges
Address
74,rue du Faubourg Saint-Antoine, Paris, FRA, 75012
Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence, and Optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group focus is on ophthalmology where it develops product candidates to restore eyesight to patients suffering from retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.

Gensight Biologics (XPAR:SIGHT) Headlines

No Headlines